

FILED

IN THE UNITED STATES DISTRICT COURT  
FOR THE EASTERN DISTRICT OF VIRGINIA  
(Alexandria Division)

2007 OCT -9 P 4:53

CLERK US DISTRICT COURT  
ALEXANDRIA, VIRGINIA

SMITHKLINE BEECHAM  
CORPORATION,  
d/b/a GLAXOSMITHKLINE,  
SMITHKLINE BEECHAM PLC, and  
GLAXO GROUP LIMITED, d/b/a  
GLAXOSMITHKLINE,

Plaintiffs,

v.

JON W. DUDAS, in his official capacity  
as Under Secretary of Commerce  
for Intellectual Property and Director  
of the United States Patent and  
Trademark Office, and

UNITED STATES PATENT AND  
TRADEMARK OFFICE,

Defendants.

Civil Action No. 1-07 CV 1008  
CMH/TRJ

**PLAINTIFFS' CORPORATE DISCLOSURE STATEMENT**  
**PURSUANT TO FED. R. CIV. P. 7.1 AND LOCAL RULE 7.1**

Pursuant to Federal Rule of Civil Procedure 7.1 and Local Rule 7.1, the undersigned counsel for Plaintiffs SmithKline Beecham plc, Glaxo Group Ltd., and SmithKline Beecham Corporation d/b/a GlaxoSmithKline (collectively referred to as "GSK") respectfully submit the following corporate disclosure statement:


1. SmithKline Beecham plc, Glaxo Group Limited and SmithKline Beecham Corporation are all wholly-owned subsidiaries of GlaxoSmithKline plc ("GSK plc"). GSK plc is a publicly traded public limited company organized under the laws of England. Its ordinary

shares are traded on the London Stock Exchange and in the form of American depositary shares on the New York Stock Exchange. No publicly held corporation owns 10 percent or more of GSK plc's outstanding shares.

2. The following are parents, subsidiaries and/or affiliates of the plaintiffs that have issued shares or debt securities to the public: Amoun Pharmaceutical Industries Co. S.A.E., Burroughs Wellcome Limited, Glaxo Wellcome Ceylon Limited, GlaxoSmithKline Bangladesh Limited, GlaxoSmithKline Capital K.K., GlaxoSmithKline Capital plc, GlaxoSmithKline Capital Inc., GlaxoSmithKline Consumer Healthcare Limited, GlaxoSmithKline Consumer Nigeria plc, GlaxoSmithKline Finance plc, GlaxoSmithKline Pakistan Limited, GlaxoSmithKline Pharmaceuticals Limited, and GlaxoSmithKline S.A.E.

Date: October 9, 2007

Respectfully submitted,

  
Elizabeth M. Locke (VSB No. 71784)  
KIRKLAND & ELLIS LLP  
655 15th Street, N.W.  
Washington, D.C. 20005  
Tel: (202) 879-5000

Of counsel:

John M. Desmarais  
Peter J. Armenio  
KIRKLAND & ELLIS LLP  
Citigroup Center  
153 East 53rd Street  
New York, New York 10022  
Tel: (212) 446-4800

F. Christopher Mizzo  
Jeffrey Bossert Clark  
D. Sean Trainor

Gregory F. Corbett  
KIRKLAND & ELLIS LLP  
655 15th Street, N.W.  
Washington, D.C. 20005  
(202) 879-5000

**ATTORNEYS FOR PLAINTIFFS**

**SmithKline Beecham Corporation d/b/a  
GlaxoSmithKline, SmithKline Beecham  
PLC, and Glaxo Group Limited d/b/a  
GlaxoSmithKline**